Assessments
tumor, Cancer
DISEASE PROGRESSION, TUMOR, ADVERSE EVENT, ADVERSE EVENTS, ADVERSE EVENT, CANCER
Postbaseline tumor assessments were collected at the following intervals: every 9 weeks, the end of the combination phase, every subsequent 12 weeks up to 2 years followed by every 6 months up to 3 years, then annually until disease progression. Plasma samples for pharmacokinetic analyses were collected on day 1 of cycles 1–4.Treatment-emergent adverse events are defined as adverse events occurring between first dose of veliparib/placebo until 30 days after the last dose. Adverse events were summarized using preferred terms within a System Organ Class according to the Medical Dictionary for Regulatory Activities and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.